Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Wasting syndrome involves the loss of both fat and lean body mass.
Abnormal body fat distribution is still a concern for many people living with HIV.
Understanding lipodystrophy among people living with HIV, including visceral fat and hard belly.
There are various options for treating the symptoms of lipodystrophy, both in terms of fat buildup and fat loss.
Older medications are more likely to cause this change in the body.
HIV-positive people are aging faster than those not infected HIV, possibly due to the body’s hyperactive response to the virus.
People with private health insurance using Serostim can now save up to $200 per month on their monthly co-payments.
Two experimental therapies may ease a big HIV-related bellyache: excess deep belly fat or visceral adipose tissue (VAT).
A new non-nuke, the apparent cure of an HIV-positive patient receiving a bone marrow transplant and the possibility of earlier...
The company also confirmed a proposed deal with EMD Serono to sell the drug in the United States once it is approved.
Theratechnologies announced today that it has sold the rights to sell the experimental lipodystrophy drug tesamorelin in the United StatesR...
FDA declined this week to approve EMD Serono’s Serostim for the treatment of HIV-associated adipose redistribution syndrome (HARS)
FDA declined this week to approve Serostim for the treatment of HIV-associated adipose redistribution syndrome (HARS).
If you used Serostim, which is only FDA-approved to treat HIV-related wasting, you many be eligible to cash in on a class action lawsuit.
The drug takers and insurance companies that paid for the injectable treatments are about to recoup some of their money.
Recombinant human growth hormone (Serostim®) has entered an unexpected area of HIV treatment research: immune-based therapies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.